HR7050Referred to Committee

Homeopathic Drug Product Safety, Quality, and Transparency Act

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-01-14
Introduced
4
Cosponsors
HR
Type

Sponsor

Pete Sessions
Pete Sessions
Republican · TX · Representative
Votes with party: 98.7% (552 recorded votes)

Full profile: /officials/S000250

Source: Congress.gov · FEC

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the House Committee on Energy and Commerce.

2026-01-14

Source: Congress.gov

Committee Activity

Currently in

Previously

Plain-English Summary

The legislation would require homeopathic products sold in the United States to meet stricter safety and quality standards, similar to those for conventional drugs, and would mandate that manufacturers clearly disclose their ingredients and manufacturing processes on product labels. This would affect homeopathic remedy makers and sellers, as well as consumers who use these products, by ensuring greater transparency about what they're buying and how it was made. The bill aims to give the FDA more authority to oversee the homeopathic industry, which currently operates under looser regulations than pharmaceutical drugs.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health
Full bill text is not yet cached locally.

Related legislation

Bills by the same sponsor or covering overlapping subjects.